$BDSX
BIODESIX INC

2021 Q2 Form 10-Q Financial Statement

#000156459021043081 Filed on August 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $11.89M $4.239M
YoY Change 180.37%
Cost Of Revenue $7.085M $3.455M
YoY Change 105.07%
Gross Profit $4.800M $5.880M
YoY Change -18.37%
Gross Profit Margin 40.39% 138.71%
Selling, General & Admin $11.43M $6.834M
YoY Change 67.18%
% of Gross Profit 238.02% 116.22%
Research & Development $3.323M $2.107M
YoY Change 57.71%
% of Gross Profit 69.23% 35.83%
Depreciation & Amortization $200.0K $200.0K
YoY Change 0.0% -85.51%
% of Gross Profit 4.17% 3.4%
Operating Expenses $22.47M $9.858M
YoY Change 127.96%
Operating Profit -$10.59M -$5.619M
YoY Change 88.41%
Interest Expense $815.0K $2.784M
YoY Change -70.73%
% of Operating Profit
Other Income/Expense, Net -$815.0K -$2.647M
YoY Change -69.21%
Pretax Income -$11.40M -$17.97M
YoY Change -36.55%
Income Tax
% Of Pretax Income
Net Earnings -$11.40M -$8.266M
YoY Change 37.94% 20.57%
Net Earnings / Revenue -95.94% -195.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$411.2K -$684.5K
COMMON SHARES
Basic Shares Outstanding 2.520M
Diluted Shares Outstanding 2.520M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.35M $11.70M
YoY Change 381.62%
Cash & Equivalents $56.35M $11.70M
Short-Term Investments
Other Short-Term Assets $6.820M $3.000M
YoY Change 127.33%
Inventory
Prepaid Expenses
Receivables $5.281M $2.900M
Other Receivables $0.00 $0.00
Total Short-Term Assets $68.45M $17.60M
YoY Change 288.92%
LONG-TERM ASSETS
Property, Plant & Equipment $3.378M $2.000M
YoY Change 68.9%
Goodwill $15.03M
YoY Change
Intangibles $12.40M
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.545M $100.0K
YoY Change 2445.0%
Total Long-Term Assets $33.35M $27.90M
YoY Change 19.55%
TOTAL ASSETS
Total Short-Term Assets $68.45M $17.60M
Total Long-Term Assets $33.35M $27.90M
Total Assets $101.8M $45.50M
YoY Change 123.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.160M $900.0K
YoY Change 28.89%
Accrued Expenses $6.198M $3.100M
YoY Change 99.94%
Deferred Revenue $2.200M
YoY Change
Short-Term Debt $0.00 $24.30M
YoY Change -100.0%
Long-Term Debt Due $3.106M $4.100M
YoY Change -24.24%
Total Short-Term Liabilities $21.27M $45.00M
YoY Change -52.73%
LONG-TERM LIABILITIES
Long-Term Debt $29.96M $23.30M
YoY Change 28.56%
Other Long-Term Liabilities $1.587M $29.70M
YoY Change -94.66%
Total Long-Term Liabilities $54.76M $53.00M
YoY Change 3.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.27M $45.00M
Total Long-Term Liabilities $54.76M $53.00M
Total Liabilities $76.03M $98.00M
YoY Change -22.42%
SHAREHOLDERS EQUITY
Retained Earnings -$277.2M
YoY Change
Common Stock $27.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.77M -$243.0M
YoY Change
Total Liabilities & Shareholders Equity $101.8M $45.50M
YoY Change 123.75%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$11.40M -$8.266M
YoY Change 37.94% 20.57%
Depreciation, Depletion And Amortization $200.0K $200.0K
YoY Change 0.0% -85.51%
Cash From Operating Activities $1.094M -$8.840M
YoY Change -112.38% -9.61%
INVESTING ACTIVITIES
Capital Expenditures -$344.0K -$320.0K
YoY Change 7.5% -62.35%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$500.0K
YoY Change -100.0%
Cash From Investing Activities -$344.0K -$820.0K
YoY Change -58.05% -3.53%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 279.0K 16.05M
YoY Change -98.26% 60.82%
NET CHANGE
Cash From Operating Activities 1.094M -8.840M
Cash From Investing Activities -344.0K -820.0K
Cash From Financing Activities 279.0K 16.05M
Net Change In Cash 1.029M 6.390M
YoY Change -83.9% -1083.08%
FREE CASH FLOW
Cash From Operating Activities $1.094M -$8.840M
Capital Expenditures -$344.0K -$320.0K
Free Cash Flow $1.438M -$8.520M
YoY Change -116.88% -4.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
bdsx Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1
P9Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M24D
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
23352000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14914000
CY2020Q2 us-gaap Interest Expense
InterestExpense
2784000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8710000
CY2021Q2 us-gaap Other Assets Current
OtherAssetsCurrent
6820000
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56349000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62126000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5281000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Goodwill
Goodwill
15031000
CY2020Q4 us-gaap Goodwill
Goodwill
15031000
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12400000
CY2021Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
54759000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
13260000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3532000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3178000
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
29955000
CY2021Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
23217000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
34930000
CY2021Q2 us-gaap Assets
Assets
101804000
CY2020Q4 us-gaap Assets
Assets
121070000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1160000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8964000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6198000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2182000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
68450000
CY2021Q2 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
3106000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
86140000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
21272000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3378000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1587000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2545000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3461000
CY2021Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
33354000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7789000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-258814000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41166000
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
168000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
180000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15304000
CY2021Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
8626000
CY2020Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
11840000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32125000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
15926000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
29932000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1921000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
47779000
CY2021Q2 us-gaap Liabilities
Liabilities
76031000
CY2020Q4 us-gaap Liabilities
Liabilities
79904000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26948879
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26948879
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26561504
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26561504
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
27000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
299953000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
121070000
CY2021Q2 us-gaap Revenues
Revenues
11885000
CY2020Q2 us-gaap Revenues
Revenues
4239000
us-gaap Revenues
Revenues
40751000
us-gaap Revenues
Revenues
9335000
CY2021Q2 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
7085000
CY2020Q2 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
1874000
bdsx Direct Costs And Expenses
DirectCostsAndExpenses
25303000
bdsx Direct Costs And Expenses
DirectCostsAndExpenses
3455000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3323000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2107000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6644000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5007000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11425000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6834000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-277177000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
25773000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
101804000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
302923000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11778000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-68.85
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
275000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27020000
CY2021Q2 bdsx Change In Fair Value Of Contingent Consideration Excluding Accretion Expense
ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense
639000
CY2020Q2 bdsx Change In Fair Value Of Contingent Consideration Excluding Accretion Expense
ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense
-957000
bdsx Change In Fair Value Of Contingent Consideration Excluding Accretion Expense
ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense
1622000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
22472000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
9858000
us-gaap Operating Expenses
OperatingExpenses
56921000
us-gaap Operating Expenses
OperatingExpenses
23376000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10587000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5619000
CY2021Q2 us-gaap Interest Expense
InterestExpense
815000
us-gaap Net Income Loss
NetIncomeLoss
-17971000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-30.06
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
261000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
204000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
539000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11402000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
25773000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-225139000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9705000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-728000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
256000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2647000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2193000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3930000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11402000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8266000
us-gaap Net Income Loss
NetIncomeLoss
-18363000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27730000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41166000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
475000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1752000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6961000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
36432000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-234833000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
55000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8266000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-243044000
us-gaap Profit Loss
ProfitLoss
-18363000
us-gaap Profit Loss
ProfitLoss
-17971000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1523000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1391000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2611000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-728000
us-gaap Share Based Compensation
ShareBasedCompensation
2291000
us-gaap Share Based Compensation
ShareBasedCompensation
55000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
1622000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
193000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
113000
bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
502000
bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
662000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9830000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2233000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1794000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
876000
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
-447000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-9453000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-210000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1350000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3152000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10236000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8840000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
747000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
232000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
109000
bdsx Proceeds From Issuance Of Term Loan And Notes Payable
ProceedsFromIssuanceOfTermLoanAndNotesPayable
30078000
bdsx Proceeds From Issuance Of Term Loan And Notes Payable
ProceedsFromIssuanceOfTermLoanAndNotesPayable
3085000
bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
117000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-864000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-818000
bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
86000
bdsx Payments To Acquire Oncimmune
PaymentsToAcquireOncimmune
500000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
12955000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
679000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
11000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
25419000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5229000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5871000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62306000
bdsx Number Of Cancer Test
NumberOfCancerTest
4
bdsx Number Of Commercial Blood Based Test
NumberOfCommercialBloodBasedTest
2
bdsx Number Of Sars Co V2 Test
NumberOfSARSCoV2Test
3
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the balance sheet date and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Uncertainties</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company’s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.  Restricted cash consists of deposits related to the Company’s corporate credit cards and prior to March 31, 2021, also included a letter of credit related to an operating lease agreement. As of June 30, 2021 and December 31, 2020, the Company had $0.1 million and $0.2 million in restricted cash, respectively, which was included in ‘Other current assets’ in the accompanying balance sheets.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a discussion of credit risk concentration of accounts receivable as of June 30, 2021 and 2020, see Note 9 – Revenue &amp; Accounts Receivable Credit Concentration.</p>
CY2020Q2 bdsx Put Option Liability Current
PutOptionLiabilityCurrent
3300000
CY2021Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2028-02-23
CY2021Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
300000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-100000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10471000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9902000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7093000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6724000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3378000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3178000
CY2021Q2 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
500000
CY2020Q2 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
400000
CY2021Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18566000
CY2021Q2 bdsx Intangible Assets Accumulated Amortization Excluding Goodwill
IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
6166000
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12400000
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18448000
CY2020Q4 bdsx Intangible Assets Accumulated Amortization Excluding Goodwill
IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
5188000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
13260000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000.0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000.0
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
976000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1951000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1947000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1940000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1936000
CY2021Q2 bdsx Finite Lived Intangible Assets Amortization Expense Year Five And Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter
3574000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
12324000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6198000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7789000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2117000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3975000
CY2021Q2 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
842000
CY2020Q4 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
715000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3239000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3099000
CY2021Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
109000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
313000
CY2021Q2 us-gaap Notes Payable
NotesPayable
33061000
CY2020Q4 us-gaap Notes Payable
NotesPayable
27766000
CY2021Q2 us-gaap Notes Payable Current
NotesPayableCurrent
3106000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
11840000
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
29955000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
15926000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
691000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2423000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
15000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
13217000
CY2021Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
14418000
CY2021Q2 bdsx Long Term Debt Maturities Repayments Of Principal In Year Five And Thereafter
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter
2406000
CY2021Q2 us-gaap Long Term Debt
LongTermDebt
33170000
us-gaap Interest Paid Net
InterestPaidNet
700000
CY2020Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
118766273
CY2020Q4 bdsx Number Of Preferred Stock Converted Into Common Stock
NumberOfPreferredStockConvertedIntoCommonStock
20090745
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q2 us-gaap Revenues
Revenues
11885000
CY2020Q2 us-gaap Revenues
Revenues
4239000
us-gaap Revenues
Revenues
40751000
us-gaap Revenues
Revenues
9335000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3500000
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1900000
bdsx Contract With Customer Liability Reclassified From Non Current Liabilities
ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities
600000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2200000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
539000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
55000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2291000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
55000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2321000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.82
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
42580000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1041000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.39
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
122000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.64
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
366000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.43
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2874000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.17
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
20806000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1267000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.89
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
165507000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11402000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8266000
us-gaap Net Income Loss
NetIncomeLoss
-18363000
us-gaap Net Income Loss
NetIncomeLoss
-17971000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27730000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
275000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27020000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
261000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-30.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-68.85
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3096000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2021Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2020Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2021Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
600000
CY2020Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
500000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1100000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
352000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
724000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
112000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1188000

Files In Submission

Name View Source Status
0001564590-21-043081-index-headers.html Edgar Link pending
0001564590-21-043081-index.html Edgar Link pending
0001564590-21-043081.txt Edgar Link pending
0001564590-21-043081-xbrl.zip Edgar Link pending
bdsx-10q_20210630.htm Edgar Link pending
bdsx-10q_20210630_htm.xml Edgar Link completed
bdsx-20210630.xsd Edgar Link pending
bdsx-20210630_cal.xml Edgar Link unprocessable
bdsx-20210630_def.xml Edgar Link unprocessable
bdsx-20210630_lab.xml Edgar Link unprocessable
bdsx-20210630_pre.xml Edgar Link unprocessable
bdsx-ex1037_47.htm Edgar Link pending
bdsx-ex1038_489.htm Edgar Link pending
bdsx-ex1052_236.htm Edgar Link pending
bdsx-ex311_8.htm Edgar Link pending
bdsx-ex312_9.htm Edgar Link pending
bdsx-ex321_7.htm Edgar Link pending
bdsx-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending